BIOTECH XYZ

✨ BIOTECH XYZ and Biolabs@NYULangone "The Diagnostic Odyssey & Beyond: Rare Genetic Diseases" Panelist Spotlight: Elizabeth Brim ✨ Elizabeth Brim is an associate in the Washington, DC office of Covington & Burling LLP. Brim's practice includes counseling clients on compliance with the complex web of health information privacy laws and regulations, such as HIPAA, the FTC’s Health Breach Notification Rule, state medical and consumer health privacy laws, state consumer privacy laws, and genetic privacy laws. Brim will be one of the panelists of "The Diagnostic Odyssey & Beyond: Rare Genetic Diseases" on November 14th. Register now: https://lu.ma/kse6vihv 📅 Thursday, November 14 @ 5:30pm 📍 Biolabs @ NYU Langone This event is sponsored by Covington & Burling LLP and Biolabs@NYULangone. #biotech #biotechevents #biotechnyc #biotechxyz #biolabs

We are excited to co-host an insightful panel discussion on “The Diagnostic Odyssey and Beyond: Rare Genetic Diseases” on November 14th with BIOTECH XYZ and Covington & Burling LLP! Join us to explore challenges in diagnosing and treating rare genetic diseases from diagnostic delays and healthcare disparities to regulatory hurdles. Panelists will discuss balancing innovation with market success and ensuring equitable access to treatments. Panelists: •Elizabeth Brim: Covington & Burling LLP •Nikul Shukla: Johnson & Johnson •Xiao Peng PhD: Montefiore Health System Moderated by Dr. Glennis Mehra, Biolabs@NYULangone. Register here: https://lu.ma/kse6vihv

We are excited to announce our next panelist event "The Diagnostic Odyssey and Beyond: Rare Genetic Diseases" on November 14! We will explore key challenges in diagnosing and treating rare genetic diseases, focusing on diagnostic delays, healthcare disparities, and regulatory hurdles. Discussions will cover the commercialization of molecular medicines, the balance between scientific innovation and market success, and ensuring equitable access to life-saving treatments. Moderated by Dr. Glennis Mehra, Director at Biolabs@NYULangone. 📝 Register Now! https://lu.ma/kse6vihv 📅 Thursday, November 14, 2024 @ 5:30pm 📍 Biolabs @ NYU Langone Our Panel: - Elizabeth Brim, Associate at Covington & Burling LLP - Nikul Shukla, Group Product Director of Marketing at Johnson & Johnson - Xiao Peng, Assistant Professor in the Division of Genetics, Department of Pediatrics Montefiore Health System; Co-Director of the New York Center for Rare Diseases This event is sponsored by Covington & Burling LLP and Biolabs@NYULangone. #biotech #biotechxyz #biotechnyc #nycevents

"Curing Costs: How Can We Pay for Gene Therapy" Highlights, hosted by BIOTECH XYZ and Foley & Lardner LLP on September 25th. Our panel on this evening highlighted the affordability, challenges, current condition and future prospects of gene therapy. Thanks to our panelists, Dr. Efrat Eliyahu (Co-Founder of Senex Therapeutics), Andrew Steinsapir (Gene Therapy Program Lead at Deerfield Management; CTO at Apertura Gene Therapy), and Brittany Woods (Associate Director, Strategic and Competitive Insights at Prevail Therapeutics), for their expertise and insights; and to Ellen Horste, PhD for moderating the conversation. Thanks to all who attended our event! Join our listserv to be updated on our future events: https://lnkd.in/eS-vrubR Thanks to Foley & Lardner LLP for sponsoring this event! #biotech #biotechnyc #biotechxyz #genetherapy

🌟 BIOTECH XYZ & Foley & Lardner LLP: Curing Costs - How Can We Pay for Gene Therapy? 🌟 What an incredible evening last week to kick off our fall season! Our "Curing Costs: How Can We Pay for Gene Therapy?" event was a huge success, bringing together industry experts, innovators, and a passionate audience to dive deep into one of the most pressing issues in healthcare today. Thank you to all who attended and participated — we couldn't have asked for a more interactive, inspiring evening! A big thank you to our brilliant panelists: Dr. Efrat Eliyahu (Co-Founder, Senex Therapeutics), Andrew Steinsapir (Gene Therapy Program Lead, Deerfield Management; CTO, Apertura Gene Therapy), and Brittany Woods (Associate Director, Strategic and Competitive Insights, Prevail Therapeutics, Eli Lilly and Company) And a special thanks to Ellen Horste, PhD, who moderated the conversation, ensuring that every voice was heard and guiding the discussion through thoughtful, impactful questions. You are an excellent representative for our team, marking our first self-moderating panel successful. We also want to extend our deepest gratitude to Foley & Lardner LLP, especially Benjamin Bassoff and Evan Hellman, for being such great co-hosts and sponsors, helping us foster lively discussions and meaningful networking opportunities. 💡🔬Stay tuned for more events and discussions from BIOTECH XYZ in this season. #GeneTherapy #HealthcareInnovation #CuringCosts #BIOTECH #Networking #Biopharma #FoleyLardner #EventSuccess

Such an insightful panel yesterday chatting about all things cell and gene therapy! The group covered the major challenges in developing a cell or gene therapy, where the opportunities for innovation within this process may be, and how we can keep costs in mind. The consensus was that the costs are so high NOT because of the how much it costs to develop and commercialize them, but rather because they have a different paradigm in which they capture value and that the prices reflect that difference. In terms of how to lower the prices? Well, the jury is still out on how to best crack that nut. I feel like I'm still dipping my toes into the cell and gene therapy space, so this was a great opportunity for me to learn more about it and to meet some of the people working on the newest technologies! Thanks to Foley & Lardner LLP and BIOTECH XYZ for hosting the event, and a shoutout to Ellen Horste, PhD, for her wonderful job moderating the panel!

✨BIOTECH XYZ & Foley & Lardner LLP "Curing Costs" Speaker Spotlight: Efrat Eliyahu ✨ Efrat Eliyahu, PhD, is an Assistant Professor with the Department of Genetics and Genomic Sciences at Icahn School of Medicine at Mount Sinai and Co-Founder of Senex Therapeutics. The Eliyahu lab studies the role of sphingolipid metabolism in regulating cell survival under optimal physiological conditions and response to stress. Senex Therapeutics was founded in 2022, with the mission of reversing chronic inflammation and aging through metabolic gene therapy. Eliyahu will be one of the panelists at our "Curing Costs: How Can We Pay for Gene Therapy" event on September 25, with other industry experts to outline the problem of the costs of gene therapy and brainstorm solutions that are creative, clever, and practical. Reserve your spot now: https://lu.ma/b83937nu 📅 September 25 @ 6pm 📍 Foley & Lardner #genetherapy #biotechevents #biotechnyc

Only 4 DAYS LEFT to sign up for BIOTECH XYZ x Foley & Lardner LLP Panel Discussion on “Curing Costs: How Can We Pay for Gene Therapy” happening next Wednesday, September 25th! The value of gene therapy drugs to society at large is undeniable: restoring sight to patients with hereditary blindness, hearing to patients with hereditary deafness, mobility to patients with inherited muscular atrophy disorders. The multi-million-dollar price tags, however, are leaving both patients and payers with sticker-shock side effects. Registration CLOSES at 5PM Monday September 23rd. Register Now! https://lu.ma/b83937nu Our panelists: • Brittany Woods, Associate Director of Strategic and Competitive Insights at Prevail Therapeutics • Andrew Steinsapir, Director, Gene Therapy Program Lead at Deerfield Management • Efrat Eliyahu, Assistant Professor with the Department of Genetics and Genomic Sciences at Icahn School of Medicine at Mount Sinai and Founder of Senex Therapeutics This event is sponsored by Foley & Lardner LLP.

✨BIOTECH XYZ & Foley & Lardner LLP "Curing Costs" Speaker Spotlight: Andrew Steinsapir ✨ Andrew Steinsapir is a Director, Gene Therapy Program Lead at Deerfield Management and Acting Chief Technology Officer at Apertura Gene Therapy, a Deerfield portfolio company. Prior to Deerfield Management, Steinsapir worked in several research and process development roles then provided strategic and tactical support for more than 30 cell and gene therapy firms, pharma, and investment firms at Dark Horse Consultant Group. He will be one of the panelists at our "Curing Costs: How Can We Pay for Gene Therapy" event on September 25, with other industry experts to outline the problem of the costs of gene therapy and brainstorm solutions that are creative, clever, and practical. Reserve your spot now: https://lu.ma/b83937nu 📅 September 25 @ 6pm 📍 Foley & Lardner #genetherapy #biotechevents #biotechnyc

✨BIOTECH XYZ & Foley & Lardner LLP "Curing Costs" Speaker Spotlight: Brittany Woods ✨ Brittany Woods is the Associate Director of Strategic and Competitive Insights at Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly & Co.. She contributes to strategic decisions on internal programs to help guide the advancement of Prevail’s pipeline along with the preclinical and clinical teams. She will be one of the panelists at our "Curing Costs: How Can We Pay for Gene Therapy" event on September 25, with other industry experts to outline the problem of the costs of gene therapy and brainstorm solutions that are creative, clever, and practical. Reserve your spot now: https://lu.ma/b83937nu 📅 September 25 @ 6pm 📍 Foley & Lardner #genetherapy #biotechevents #biotechnyc